Investor Brings Class Suit Over Surprise Diabetes Drug Delay
Biopharmaceutical company Provention Bio Inc. misled its shareholders about the pending approval of its type 1 diabetes drug and caused a stock drop of almost 18%, according to a proposed class...To view the full article, register now.
Already a subscriber? Click here to view full article